Nakagawa K, Fukuyama T, Oishi K, Kounami T
Jpn J Antibiot. 1977 Oct;30(10):819-23.
S-6436 was orally given to the patients mainly with uncomplicated acute cystitis at two divided doses for 7 days with the following results: 1) One or 2g/day of S-6436 were administered to the patients with 93.7% of effectiveness. There is almost no difference in effectiveness between 1 g and 2g dosages. 2) Bacteria in urine disappeared in 74% of the patients treated and superinfection occurred in 22%. The disappearance of the bacteria was observed in 83.3% of the patients with E. coli and 60% with Staph. epidermidis. The superinfection however was observed in 16.5% with E. coli and 33.3% with Staph. epidermidis. The disappearance of bacteria was observed in each one case with Klebsiella, Staph. aureus and Ps. aeruginosa. The superinfection was observed in 2 cases with Proteus. 3) Sensitivity tests on the organisms indicated that 94.4% of E. coli, 40% of Staph. epidermidis, Klebsiella and Staph. aureus were susceptible to the drug but Proteus and Ps. aeruginosa were not susceptible. 4) No remarkable side effects were observed, though digestive was used in several patients. From the above results, S-6436 is considered to be a useful drug which is expected to have as much effectiveness as regular cephalexin at two divided doses after breakfast and dinner.
S - 6436主要给予单纯性急性膀胱炎患者，分两次口服，疗程7天，结果如下：1）给予患者1或2g/天的S - 6436，有效率为93.7%。1g和2g剂量的有效性几乎没有差异。2）治疗患者中74%的尿液细菌消失，22%发生二重感染。大肠杆菌患者中83.3%观察到细菌消失，表皮葡萄球菌患者中60%观察到细菌消失。然而，大肠杆菌患者中16.5%观察到二重感染，表皮葡萄球菌患者中33.3%观察到二重感染。肺炎克雷伯菌、金黄色葡萄球菌和铜绿假单胞菌各有1例观察到细菌消失。变形杆菌有2例观察到二重感染。3）对这些微生物的敏感性试验表明，94.4%的大肠杆菌、40%的表皮葡萄球菌、肺炎克雷伯菌和金黄色葡萄球菌对该药物敏感，但变形杆菌和铜绿假单胞菌不敏感。4）尽管有几名患者使用了消化药物，但未观察到明显的副作用。从上述结果来看，S - 6436被认为是一种有用的药物，预计在早餐和晚餐后分两次服用时，其有效性与常规头孢氨苄相当。
